Stay updated on Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedNo substantive changes detected in core content; study details, eligibility criteria, and outcome measures appear unchanged.SummaryDifference0.1%

- Check26 days agoChange DetectedRevision updated to v3.5.0, replacing v3.4.3; no study content or user functionality is affected.SummaryDifference0.1%

- Check33 days agoChange Detected- Revision tag updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded a new condition term, Primary peritoneal carcinoma, and a new external resource (Genetic and Rare Diseases Information Center) for patient education. The page update also includes a new Revision (v3.4.2) and removal of the prior funding-notice (v3.4.1).SummaryDifference0.6%

- Check69 days agoChange DetectedAdded a government funding notice indicating the NIH Clinical Center is open. Updated the page to Revision: v3.4.1 (replacing v3.4.0).SummaryDifference0.5%

- Check76 days agoChange DetectedAdded a glossary toggle and updated the revision label to v3.4.0, with minor capitalization and wording adjustments to metadata. These changes are cosmetic and do not alter the study content.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.